Authors:
Address: Infectious Diseases Institute, Makerere University, Kampala, Uganda. pbyakika@idi.co.ug
Journal:

Publication:

abstract

BACKGROUND:

Treatment of HIV/malaria-coinfected patients with antiretroviral therapy (ART) and artemisinin-based combination therapy has potential for drug interactions. We investigated the pharmacokinetics of artemether, dihydroartemisinin and lumefantrine after administration of a single dose of 80/480 mg of artemether/lumefantrine to HIV-infected adults, taken with and without Lopinavir/ritonavir.

METHODS:

A two-arm parallel study of 13 HIV-infected ART-naive adults and 16 HIV-infected adults stable on 400/100 mg of lopinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors (ClinicalTrials.gov, NCT 00619944). Each participant received a single dose of 80/480 mg of artemether/lumefantrine under continuous cardiac function monitoring. Plasma concentrations of artemether, dihydroartemisinin and lumefantrine were measured.

RESULTS:

Co-administration of artemether/lumefantrine with lopinavir/ritonavir significantly reduced artemether maximum concentration (C(max)) and area under the concentration-time curve (AUC) [median (range): 112 (20-362) versus 56 (17-236) ng/mL, P = 0.03; and 264 (92-1129) versus 151 (38-606) ng · h/mL, P < 0.01]. Dihydroartemisinin C(max) and AUC were not affected [66 (10-111) versus 73 (31-224) ng/mL, P = 0.55; and 213 (68-343) versus 175 (118-262) ng · h/mL P = 0.27]. Lumefantrine C(max) and AUC increased during co-administration [2532 (1071-5957) versus 7097 (2396-9462) ng/mL, P < 0.01; and 41,119 (12,850-125,200) versus 199,678 (71,205-251,015) ng · h/mL, P < 0.01].

CONCLUSIONS:

Co-administration of artemether/lumefantrine with lopinavir/ritonavir significantly increases lumefantrine exposure, but decreases artemether exposure. Population pharmacokinetic and pharmacodynamic trials will be highly valuable in evaluating the clinical significance of this interaction and determining whether dosage modifications are indicated.

Related Articles
Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients.
Antimicrob Agents Chemother. 2...
Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients.
Kredo T, Mauff K, Van der Walt JS, Wiesner L, Maartens G, Cohen K, Smith P, Barnes KI. Antimicrob Agents Chemother. 2011 Dec; 55(12):5616-23. Epub 2011 Sep 26.
Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers.
J Acquir Immune Defic Syndr. 2...
Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers.
German P, Parikh S, Lawrence J, Dorsey G, Rosenthal PJ, Havlir D, Charlebois E, Hanpithakpong W, Lindegardh N, Aweeka FT. J Acquir Immune Defic Syndr. 2009 Aug 1; 51(4):424-9.
Review Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Drugs. 2003
Review Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS, Goa KL. Drugs. 2003; 63(8):769-802.
Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
Antivir Ther. 2007
Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
Waters LJ, Moyle G, Bonora S, D'Avolio A, Else L, Mandalia S, Pozniak A, Nelson M, Gazzard B, Back D, et al. Antivir Ther. 2007; 12(5):825-30.
Review Understanding the pharmacokinetics of Coartem.
Malar J. 2009
Review Understanding the pharmacokinetics of Coartem.
Djimdé A, Lefèvre G. Malar J. 2009 Oct 12; 8 Suppl 1:S4. Epub 2009 Oct 12.

To top • Home

---

Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer • webmaster